Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MC5R | P33032 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | MC1R | Q01726 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5939683 | 0.87 | FOLH1 (0.60) | TDP1KMT2AMEN1MAPTL3MBTL1 | |
| SCHEMBL16034081 | 0.83 | MTNR1A (0.60) | TDP1KMT2AMEN1MAPTCYP1A2 | |
| SCHEMBL29860607 | 0.83 | MTNR1A (0.60) | TDP1KMT2AMEN1MAPTCYP1A2 | |
| SCHEMBL4679636 | 0.82 | ATM (0.55) | TDP1KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL6008064 | 0.81 | MC5R (0.70) | KMT2AMEN1MAPTL3MBTL1CYP1A2 | |
| Hydrochloric Acid SCHEMBL8439823 | 0.81 | ATM (0.54) | TDP1KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL7393110 | 0.81 | KMT2A (0.50) | TDP1KMT2AMEN1MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL4236114 | 0.81 | KMT2A (0.48) | TDP1KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL21447680 | 0.79 | MC5R (0.51) | KMT2AMEN1MAPTALDH1A1L3MBTL1 | |
| SCHEMBL20422723 | 0.79 | KMT2A (0.63) | TDP1KMT2AMEN1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203096-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4139326-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021217047-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-28 | — | — | WO | disclosed |
| US-9938321-B2 | Cyclic peptoid oligomers, pharmaceutical compositions and methods of using the same | NEW YORK UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20180051056-A1 | SYNTHETIC MINIATURE PROTEIN SCAFFOLDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME | KIRSHENBAUM KENT (US) | 2018-02-22 | — | — | US | disclosed |
| US-9872495-B2 | Peptoid oligomers, pharmaceutical compositions and methods of using the same | NEW YORK UNIVERSITY (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160219880-A1 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NEW YORK UNIVERSITY | 2016-08-04 | — | — | US | disclosed |
| US-9364449-B2 | Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same | NEW YORK UNIVERSITY (US) | 2016-06-14 | — | — | US | disclosed |
| US-9315548-B2 | Peptoid oligomers, pharmaceutical compositions and methods of using the same | NEW YORK UNIVERSITY (US) | 2016-04-19 | — | — | US | disclosed |
| WO-2015175770-A1 | HDAC INHIBITORS AS ANTI-CANCER AGENTS | THE UNIVERSITY OF TOLEDO (US) | 2015-11-19 | — | — | WO | disclosed |
| US-20120015883-A1 | Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-01-19 | — | — | US | disclosed |
| EP-2401264-A2 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | New York University (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2011156003-A2 | PEPTOID AND SYNTHETIC OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2011-12-15 | — | — | WO | disclosed |
| EP-2383281-A2 | Prion-specific peptoid reagents | Novartis AG (CH) | 2011-11-02 | — | — | EP | disclosed |
| US-20110189692-A1 | ASSAY FOR PATHOGENIC CONFORMERS | NOVARTIS AG | 2011-08-04 | — | — | US | disclosed |
| WO-2011057029-A1 | POSITIVELY CHARGED SPECIES AS BINDING REAGENTS IN THE SEPARATION OF PROTEIN AGGREGATES FROM MONOMERS | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| US-7834144-B2 | Prion-specific peptoid reagents | NOVARTIS AG (CH) | 2010-11-16 | — | — | US | disclosed |
| WO-2010098843-A2 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NEW YORK UNIVERSITY (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100222255-A1 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NEW YORK UNIVERSITY | 2010-09-02 | — | — | US | disclosed |
| US-20070087972-A1 | Prion-specific peptoid reagents | NOVARTIS AG (CH) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160219880-A1 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NOD2, VIP, NOD1 | TDP1 2148/4885KMT2A 4875/4885MEN1 2370/4885 |
| US-20120015883-A1 | Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same | APP, IAPP, PSEN1 | TDP1 632/4885KMT2A 4853/4885MEN1 1236/4885 |
| US-20230203096-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | EPHA4, EPHA1, EPHA5 | TDP1 395/4885KMT2A 1129/4885MEN1 2479/4885 |
| US-20070087972-A1 | Prion-specific peptoid reagents | PRNP, PARL, PCNP | TDP1 1545/4885KMT2A 4687/4885MEN1 2738/4885 |
| US-20180051056-A1 | SYNTHETIC MINIATURE PROTEIN SCAFFOLDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME | PRNP, SPPL2A, PFDN2 | TDP1 2251/4885KMT2A 4001/4885MEN1 382/4885 |
| US-20100222255-A1 | PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | NOD2, VIP, NOD1 | TDP1 2148/4885KMT2A 4875/4885MEN1 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.